Colimax0.6 mg

Colimax 0.6 mg are indicated for treatment of acute gout flares. And also indicated in Familial Mediterranean fever (FMF) in adults and children 4 years or older.

Drugs used in Gout

An acute attack of gout apparently occurs as a result of an inflammatory reaction to crystals of monosodium urate that are deposited in the joint tissue from hyperuric body fluids; the reaction is aggravated as more urate crystals accumulate. Leukocytes migrate to the sites where urate crystals have been deposited and try to engulf the crystals by phagocytosis. As a result lactic acid and proinflammatory enzymes are released which cause inflammation with severe pain, redness, and swelling of the affected joint. Lactic acid favors a local decrease in pH that enhances uric acid deposition. Colimax 0.6 mg inhibits the phagocytosis of uric acid by leukocytes & also diminishes the lactic acid production directly. Thus interrupts the cycle of urate crystal deposition and inflammatory response that sustains the acute attack of gout. Colimax 0.6 mg is absorbed when given orally, reaching a mean Cmax of 2.5 ng/mL (range 1.1 to 4.4 ng/mL) in 1 to 2 hours after a single dose administered under fasting conditions. The mean apparent volume of distribution is approximately 5 to 8 L/kg. Colimax 0.6 mg binding to serum protein is low (39 ± 5%), primarily to albumin regardless of concentration. CYP3A4 is involved in the metabolism of Colimax 0.6 mg to 2-O-demethylColimax 0.6 mg and 3-O-demethylColimax 0.6 mg. Plasma levels of these metabolites are minimal (less than 5% of parent drug). Following multiple oral doses (0.6 mg twice daily), the mean elimination half-life is 26.6 to 31.2 hours.

Acute gouty arthritis: First dose- 1 to 1.2 mg (two 0.5 mg or two 0.6 mg tablets) at a time every 2 hours until pain and inflammation aborted. The total amount of Colimax 0.6 mg needed to control pain and inflammation during an attack usually ranges from 4 to 8 mg. Articular pain and swelling typically reduced within 12 hours and are usually gone in 24 to 48 hours, An interval of three days between Colimax 0.6 mg courses is advised in order to minimize the possibility of cumulative toxicity. For prophylaxis during intercritical periods: To reduce the frequency of their severity, Colimax 0.6 mg may be administered continuously. In patients who have less than one attack per year, the usual dose is 0.5 or 0.6 mg per day, three or four days a week. For cases involving more than one attack per year, the usual dose is 0.5 or 0.6 mg daily. Severe cases may require two or three 0.5 mg or 0.6 mg tablets daily. For prophylaxis against attacks of gout in patients undergoing surgery: In patients with gout, an attack may be precipitated by even a minor surgical procedure. One 0.5 mg tablet or one 0.6 mg tablet three times daily should be administered for three days before and three days after surgery.

Acute gouty arthritis: First dose- 1 to 1.2 mg (two 0.5 mg or two 0.6 mg tablets) at a time every 2 hours until pain and inflammation aborted. The total amount of Colimax 0.6 mg needed to control pain and inflammation during an attack usually ranges from 4 to 8 mg. Articular pain and swelling typically reduced within 12 hours and are usually gone in 24 to 48 hours, An interval of three days between Colimax 0.6 mg courses is advised in order to minimize the possibility of cumulative toxicity. For prophylaxis during intercritical periods: To reduce the frequency of their severity, Colimax 0.6 mg may be administered continuously. In patients who have less than one attack per year, the usual dose is 0.5 or 0.6 mg per day, three or four days a week. For cases involving more than one attack per year, the usual dose is 0.5 or 0.6 mg daily. Severe cases may require two or three 0.5 mg or 0.6 mg tablets daily. For prophylaxis against attacks of gout in patients undergoing surgery: In patients with gout, an attack may be precipitated by even a minor surgical procedure. One 0.5 mg tablet or one 0.6 mg tablet three times daily should be administered for three days before and three days after surgery.

Co-administration of P-gp and/or CYP3A4 inhibitors (e.g., clarithromycin or cyclosporine) have been demonstrated to alter the concentration of Colimax 0.6 mg

Patients with renal or hepatic impairment should not be given Colimax 0.6 mg in conjunction with Permeability glycoprotein (P-gp) or strong CYP3A4 inhibitors (e.g., clarithromycin or cyclosporine).

Blood dyscrasias: Myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported. Diarrhea and pharyngolaryngeal pain may occur.

Pregnancy Category C. There are no adequate and well-controlled studies with Colimax 0.6 mg in pregnant women. Colimax 0.6 mg is excreted into human milk. Caution should be exercised when administered to a nursing woman.

The exact dose of Colimax 0.6 mg that produces significant toxicity is unknown. Fatalities have occurred after ingestion of a dose as low as 7 mg over a 4-day period, while other patients have survived after ingesting more than 60 mg. A review of 150 patients who overdosed on Colimax 0.6 mg found that those who ingested less than 0.5 mg/kg survived and tended to have milder toxicities, such as gastrointestinal symptoms, whereas those who took 0.5 to 0.8 mg/kg had more severe reactions, such as myelosuppression.

Store below 30°C temperature. Protect from light and moisture. Keep the medicine out of reach of children.

Pediatric Use: Gout is rare in pediatric patients. Safety and effectiveness of Colimax 0.6 mg in pediatric patients have not been established.

Drugs used in Gout

An acute attack of gout apparently occurs as a result of an inflammatory reaction to crystals of monosodium urate that are deposited in the joint tissue from hyperuric body fluids; the reaction is aggravated as more urate crystals accumulate. Leukocytes migrate to the sites where urate crystals have been deposited and try to engulf the crystals by phagocytosis. As a result lactic acid and proinflammatory enzymes are released which cause inflammation with severe pain, redness, and swelling of the affected joint. Lactic acid favors a local decrease in pH that enhances uric acid deposition. Colimax 0.6 mg inhibits the phagocytosis of uric acid by leukocytes & also diminishes the lactic acid production directly. Thus interrupts the cycle of urate crystal deposition and inflammatory response that sustains the acute attack of gout. Colimax 0.6 mg is absorbed when given orally, reaching a mean Cmax of 2.5 ng/mL (range 1.1 to 4.4 ng/mL) in 1 to 2 hours after a single dose administered under fasting conditions. The mean apparent volume of distribution is approximately 5 to 8 L/kg. Colimax 0.6 mg binding to serum protein is low (39 ± 5%), primarily to albumin regardless of concentration. CYP3A4 is involved in the metabolism of Colimax 0.6 mg to 2-O-demethylColimax 0.6 mg and 3-O-demethylColimax 0.6 mg. Plasma levels of these metabolites are minimal (less than 5% of parent drug). Following multiple oral doses (0.6 mg twice daily), the mean elimination half-life is 26.6 to 31.2 hours.

Pregnancy Category C. There are no adequate and well-controlled studies with Colimax 0.6 mg in pregnant women. Colimax 0.6 mg is excreted into human milk. Caution should be exercised when administered to a nursing woman.

Pediatric Use: Gout is rare in pediatric patients. Safety and effectiveness of Colimax 0.6 mg in pediatric patients have not been established.